Weifu

Wefu is a clinical-stage biopharmaceutical company based in Shanghai, China, dedicated to the discovery and development of innovative small molecule therapeutics for autoimmune diseases and oncology. The company focuses on the design of highly selective kinase inhibitors, aiming to provide safer and more effective treatment options for chronic inflammatory conditions. Its lead asset, WF-210, is a potent and selective TYK2 inhibitor currently in Phase 2 clinical development for plaque psoriasis. Wefu's pipeline also includes several other candidates targeting the JAK/STAT pathway and various oncological targets, supported by a robust internal discovery engine. The company was founded by industry veterans with extensive experience in global drug development and is backed by leading venture capital firms. Wefu aims to address significant unmet medical needs by leveraging its expertise in medicinal chemistry and translational medicine.